Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan-Dec:21:15330338221086403.
doi: 10.1177/15330338221086403.

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review

Fengying Qin  1 , Huiting Pang  1 , Tao Yu  1 , Yahong Luo  1 , Yue Dong  1
Affiliations
Review

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review

Fengying Qin et al. Technol Cancer Res Treat. 2022 Jan-Dec.

Abstract

Cervical cancer is the fourth most common malignant tumor globally in terms of morbidity and mortality. The presence of lymph node metastasis (LNM) is an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in cervical cancer patients. The International Federation of Gynecology and Obstetrics (FIGO) staging system was revised in 2018. An important revision designates patients with regional LNM as stage IIIC, pelvic LNM only as stage IIIC1, and para-aortic LNM as stage IIIC2. However, the current staging system is only based on the anatomical location of metastatic lymph nodes (LNs). It does not consider other LN status parameters, which may limit its prognostic significance to a certain extent and needs further exploration and confirmation in the future. The purpose of this review is to summarize the choice of treatment for stage IIIC cervical cancer and the effect of different LN status parameters on prognosis.

Keywords: FIGO stage; cervical cancer; concurrent chemoradiotherapy; lymph node; prognosis; surgery.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. - PubMed
    1. Koh WJ, Abu-Rustum NR, Bean S, . et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64-84. - PubMed
    1. Miyahara S, Tsuji, K, Shimada M, et al. The impact of histological subtype on survival outcome of patients with stage IIB-IVA cervical cancer who received definitive radiotherapy. Tohoku J Exp Med. 2021;255(4):303-313. - PubMed
    1. Chen W, Xiu S, Xie X, et al. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer. Radiat Oncol. 2022;17(1):6. - PMC - PubMed
    1. Brodeur MN, Dejean R Beauchemin MC, et al. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer. Gynecol Oncol. 2021;162(2):277-283. - PubMed

Publication types